FDA Approves Rasonque, First Broad RAS-Targeted Therapy, for Pancreatic Cancer

Company: Revolution Medicines · Drug: Rasonque (Daraxonrasib) · Indication: Metastatic Pancreatic Adenocarcinoma · Event Type: FDA Approval · Date: August 26, 2026 Summary FDA approved Revolution Medicines’ once-daily oral Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy…